
BI in cancer antibody discovery deal with Oxford BioTherapeutics
Executive Summary
UK oncology drug and companion diagnostic developer Oxford BioTherapeutics Ltd. (OBT) has licensed Boehringer Ingelheim GMBH exclusive rights to develop and market its cancer antibodies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com